TY - JOUR
T1 - The effect of probiotics on the incidence of Clostridioides difficile
T2 - Retrospective cohort analysis
AU - Saltzman, Temima
AU - Fazzari, Melissa
AU - Chung, Shirley
AU - Cunha, Burke A.
AU - Blum, Sharon
N1 - Publisher Copyright:
© 2019 Association for Professionals in Infection Control and Epidemiology, Inc.
PY - 2020/2
Y1 - 2020/2
N2 - Background: Conflicting evidence exists regarding probiotics and the incidence of Clostridioides difficile infection (CDI). This study evaluates whether probiotics are efficacious for CDI prophylaxis in patients receiving antibiotics. Methods: A retrospective cohort analysis of patients admitted to NYU Winthrop Hospital who received at least 1 dose of antibiotics considered high risk of inducing CDI. Patients were grouped according to probiotic use; association between probiotic use and incident CDI was examined. A model for incident CDI adjusting for known CDI risk factors was estimated. Results: Of 3,267 patients, 4.6% had CDI within 12 weeks of antibiotics initiation. A total of 5.1% received probiotics within 24 hours of initiation, and 6.6% initiated probiotics during the 12-week follow-up. Of those taking probiotics within 24 hours of antibiotics, 9.6% had CDI, and of those not taking probiotics 4.2% had CDI (relative risk, 2.3; 95% confidence interval, 1.4, 3.7). In time-dependent Cox models accounting for probiotic initiation and adjusting for potential confounders, a positive association between probiotics and CDI remained significant (hazard ratio, 2.7; P <. 001). Discussion: Patients who received antibiotics with concurrent probiotics were more likely to have an incident of CDI compared with those who did not receive probiotics. Additional risk factors were histamine 2 receptor antagonists, proton pump inhibitors, and administration of multiple antibiotics simultaneously. Conclusions: The present study, because of its large population and inclusion of multiple variables playing a role in CDI, serves as a valuable resource when considering efficacy of probiotics as CDI prophylaxis.
AB - Background: Conflicting evidence exists regarding probiotics and the incidence of Clostridioides difficile infection (CDI). This study evaluates whether probiotics are efficacious for CDI prophylaxis in patients receiving antibiotics. Methods: A retrospective cohort analysis of patients admitted to NYU Winthrop Hospital who received at least 1 dose of antibiotics considered high risk of inducing CDI. Patients were grouped according to probiotic use; association between probiotic use and incident CDI was examined. A model for incident CDI adjusting for known CDI risk factors was estimated. Results: Of 3,267 patients, 4.6% had CDI within 12 weeks of antibiotics initiation. A total of 5.1% received probiotics within 24 hours of initiation, and 6.6% initiated probiotics during the 12-week follow-up. Of those taking probiotics within 24 hours of antibiotics, 9.6% had CDI, and of those not taking probiotics 4.2% had CDI (relative risk, 2.3; 95% confidence interval, 1.4, 3.7). In time-dependent Cox models accounting for probiotic initiation and adjusting for potential confounders, a positive association between probiotics and CDI remained significant (hazard ratio, 2.7; P <. 001). Discussion: Patients who received antibiotics with concurrent probiotics were more likely to have an incident of CDI compared with those who did not receive probiotics. Additional risk factors were histamine 2 receptor antagonists, proton pump inhibitors, and administration of multiple antibiotics simultaneously. Conclusions: The present study, because of its large population and inclusion of multiple variables playing a role in CDI, serves as a valuable resource when considering efficacy of probiotics as CDI prophylaxis.
KW - C difficile
KW - Clostridioides difficile
KW - Lactobacillus: CDI
KW - probiotics
UR - http://www.scopus.com/inward/record.url?scp=85073065305&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073065305&partnerID=8YFLogxK
U2 - 10.1016/j.ajic.2019.07.026
DO - 10.1016/j.ajic.2019.07.026
M3 - Article
C2 - 31606256
AN - SCOPUS:85073065305
SN - 0196-6553
VL - 48
SP - 184
EP - 188
JO - American Journal of Infection Control
JF - American Journal of Infection Control
IS - 2
ER -